凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海医药:2013年第一季度报告

公告日期 2013-04-27
股票简称:上海医药 股票代码:601607
上海医药集团股份有限公司
    (A 股股票代码:601607)
    (H 股股票代码: 02607)
    2013 年第一季度报告
    601607,02607                                      上海医药集团股份有限公司 2013 年第一季度报告
                                        目录§1 重要提示 ......................................................................... 1§2 公司基本情况 ..................................................................... 1§3 重要事项 ......................................................................... 3§4 附录 ............................................................................. 5
    601607,02607                                         上海医药集团股份有限公司 2013 年第一季度报告§1重要提示1.1 公司全体董事出席了于 2013 年 4 月 26 日召开的第四届董事会第二十九次会议,会议通过的决议包括批准本公司截至 2013 年 3 月 31 日止三个月之第一季度业绩。1.2 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。1.3 公司第一季度财务报告未经审计。1.4
    公司负责人姓名                               周杰
    主管会计工作负责人姓名                       徐国雄
    会计机构负责人(会计主管人员)姓名           沈波公司负责人周杰先生、主管会计工作负责人徐国雄先生及会计机构负责人(会计主管人员)沈波先生声明:保证本季度报告中财务报告的真实、完整。1.5 释义本报告中,除非文义另有所指,相关财务数据均为根据中国企业会计准则等规定编制,下列词语具有下述含义:
    “本公司”、“公司”或“上海      上海医药集团股份有限公司或上海医药集团股份有限公司
                               指
    医药”                            及其子公司如适用
    “公司章程”或“章程”       指   (经不时修订的)上海医药的公司章程
    “报告期”                   指   2013 年 1 月 1 日至 2013 年 3 月 31 日的 3 个月
    “同比”                     指   与上年同期比较
    “股份”                     指   上海医药每股面值人民币 1.00 元的股份,包括 A 股和 H 股
                                    在上海证券交易所上市、并以人民币买卖的本公司内资股,
    “A 股”                     指
                                    每股面值人民币 1.00 元
                                    在香港联合交易所有限公司上市、并以港元买卖的本公司
    “H 股”                     指
                                    外资股,每股价值人民币 1.00 元
    “人民币”                   指   中国法定货币人民币
    “港元”                     指   香港法定货币港元
                                    中华人民共和国,除另有所指外,在本报告内“中国”一
    “中国”                     指
                                    词不包括香港、澳门及台湾
    “香港”                     指   香港特别行政区
    “上实集团”                 指   上海实业(集团)有限公司
    “上海上实”                 指   上海上实(集团)有限公司
    “上药集团”                 指   上海医药(集团)有限公司
    “上海盛睿”                 指   上海盛睿投资有限公司§2 公司基本情况2.1 主要会计数据及财务指标
    特别说明:
    1、报告期内,本公司实现营业收入人民币 195.9 亿元,同比增长 17.6%。实现归属于上市公司股东的净利润人民币 6.26 亿元,同比增长 8.5%。
    2、报告期内,本公司分销业务实现营业收入(合并抵销前)人民币 169.8 亿元,同比增长 17.8%。
    3、报告期内,本公司工业业务实现营业收入(合并抵销前)人民币 28.1 亿元,同比增长 11.1%,其中重点品种实现营业收入人民币 16.6 亿元,同比增长 18.5%。
    601607,02607                                          上海医药集团股份有限公司 2013 年第一季度报告
                                                                                     币种:人民币
                                                                                 本报告期末比上
                                           本报告期末          上年度期末        年度期末增减
                                                                                       (%)
    总资产(元)                             52,938,336,254.53    51,069,037,985.13              3.66
    归属于上市公司股东的所有者权益 (元)    25,262,937,447.25    24,639,299,336.20              2.53归属于上市公司股东的每股净资产(元/
                                                      9.40                9.16               2.53股)
                                                                                 比上年同期增减
                                                 年初至报告期期末
                                                                                       (%)
    经营活动产生的现金流量净额(元)                                -257,826,245.93           不适用每股经营活动产生的现金流量净额(元/
                                                                         -0.10            不适用股)
                                                             年初至报告期期      本报告期比上年
                                             报告期
                                                                   末              同期增减(%)
    归属于上市公司股东的净利润(元)            625,664,019.79      625,664,019.79               8.52
    基本每股收益(元/股)                             0.2327              0.2327               8.52扣除非经常性损益后的基本每股收益(元/
                                                  0.2168               0.2168                7.54股)
    稀释每股收益(元/股)                            0.2327               0.2327                8.52
                                                                                 增加 0.04 个百分
    加权平均净资产收益率(%)                            2.51                2.51
                                                                                               点
    扣除非经常性损益后的加权平均净资产收                                            增加 0.02 个百分
                                                      2.34                2.34
    益率(%)                                                                                     点扣除非经常性损益项目和金额:
                                                                            单位:元 币种:人民币
                          项目                                                金额
    非流动资产处置损益                                                                    91,858.29计入当期损益的政府补助,但与公司正常经营业务密切相关,
    符合国家政策规定、按照一定标准定额或定量持续享受的政府                              1,914,797.49补助除外除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                                                     2,222,200.56处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
    单独进行减值测试的应收款项减值准备转回                                                 65,000.00
    除上述各项之外的其他营业外收入和支出                                                6,663,174.69
    其他符合非经常性损益定义的损益项目                                                 34,585,556.22
    所得税影响额                                                                       -1,866,729.89
    少数股东权益影响额(税后)                                                           -845,649.34
                           合计                                                     42,830,208.022.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                      单位:股
    报告期末股东总数(户)                                            95,167(A 股)3,298(H 股)
                             前十名无限售条件流通股股东持股情况
                                 期末持有无限售条件流通
       股东名称(全称)                                                 种类
                                         股的数量
    上药集团                                      749,923,539 人民币普通股
    601607,02607                                            上海医药集团股份有限公司 2013 年第一季度报告
    HKSCC NOMINEES LIMITED                       748,507,020      境外上市外资股
                                                               人民币普通股            188,894,298
    上实集团及其全资附属子公司                   204,678,698
                                                               境外上市外资股           15,784,400
    上海盛睿                                     162,399,040      人民币普通股
    申能(集团)有限公司                            81,199,520      人民币普通股中国工商银行-广发聚丰股票
                                                  61,161,210   人民币普通股型证券投资基金中国人寿保险股份有限公司-
    分 红 - 个 人 分 红 - 005L -                  14,301,970   人民币普通股FH002 沪泰康人寿保险股份有限公司-
    分 红 - 个 人 分 红 - 019L -                  11,669,310   人民币普通股FH002 沪中国光大银行股份有限公司-
    摩根士丹利华鑫资源优选混合                       11,609,296   人民币普通股型证券投资基金泰康人寿保险股份有限公司-
                                                  11,054,842   人民币普通股投连-个险投连§3 重要事项3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因
    √适用   □不适用
                                                                             单位:元 币种:人民币
    合并资产负债表项目        2013 年 3 月 31 日 2012 年 12 月 31 日 变动比例 变动原因
    交易性金融资产                    383,999.80        2,920,478.96 -86.85% 本报告期部分出售交易性金融资产
    应收利息                      24,458,861.09       15,333,869.26 59.51% 本报告期期末应收存款利息增加
    应收股利                      72,545,812.30       21,027,811.90 245.00% 本报告期参股企业宣告分配股利
    其他流动资产                 130,348,810.68      455,393,423.90 -71.38% 本报告期未抵扣增值税进项税金减少
    工程物资                      13,359,980.73         5,739,925.93 132.76% 本报告期工程项目投入增加
    应付利息                      28,737,393.72       21,731,283.11 32.24% 本报告期期末应付利息增加
    长期借款                      53,378,356.91       40,772,765.91 30.92% 本报告期长期借款增加
    合并利润表项目                2013 年 1-3 月         上年同期数 变动比例 变动原因
    营业税金及附加                 66,158,111.66      46,319,439.76 42.83% 本报告期业务增长
    资产减值损失                  10,836,293.91       -2,419,881.68          - 本报告期计提减值准备增加
    财务费用                      32,243,253.75       65,245,006.85 -50.58% 本报告期财务费用支出减少
    营业外收入                      9,729,250.68      25,980,005.00 -62.55% 本报告期营业外收益减少
    营业外支出                      1,059,420.21        5,638,439.82 -81.21% 本报告期营业外损失减少
    合并现金流量表项目            2013 年 1-3 月         上年同期数 变动比例 变动原因
    经营活动产生的现金流量净额 -257,826,245.93       -24,476,406.64          - 报告期内货款回笼放缓
    投资活动产生的现金流量净额 -232,097,064.04      -115,622,812.93          - 报告期内投资活动支出增加
    筹资活动产生的现金流量净额 -115,488,144.23      -331,251,980.91          - 报告期内筹资活动净流入增加3.2 重大事项进展情况及其影响和解决方案的分析说明□适用 √不适用3.3 公司、股东及实际控制人承诺事项履行情况√适用 □不适用
    详见《上海医药集团股份有限公司关于上市公司股东、关联方以及上市公司承诺履行情况的公告》(公司公告临 2012-025 号)。
    601607,02607                                         上海医药集团股份有限公司 2013 年第一季度报告
    自以上公告披露日(2012 年 10 月 31 日)至本报告披露日,本公司股东、关联方以及本公司所做的相关承诺进展情况如下:
    1、上药集团、上海上实关于股份锁定的承诺
    上药集团、上海上实分别承诺自重大资产重组涉及的非公开发行完成之日起 36 个月内,不转让其拥有权益的上海医药股份,相关股份的限售期承诺现已期满,该承诺已履行完毕,相关限售股上市流通日为 2013 年 2 月 18 日(详见公司公告临 2013-001 号)。
    2、上药集团关于清理和规范内部职工股和职工持股会的承诺
    2013 年 3 月 12 日,经本公司第四届董事会第二十六次会议审议通过,同意本公司以人民币 4.444亿元(以国有资产监督管理部门最终备案金额为准)向杭州市正大青春宝职工持股会收购其持有的正大青春宝药业有限公司 20%的股权(详见公司公告临 2013-002 号、临 2013-003 号)。截至 2013 年 4月 22 日,该事宜已完成股权交割、外资主管部门核准及工商变更。
    3、上药集团、上海上实关于利润预测补偿的承诺
    重大资产重组中部分采用收益法评估的上药集团购入资产以及上海实业控股有限公司购入资产中:上药集团购入资产的 2012 年度实际盈利已实现利润预测数,实现率为 148.30%;上海实业控股有限公司购入资产的 2012 年度实际盈利未实现利润预测数,实现率为 86.85%。普华永道中天会计师事务所有限公司出具了《实际盈利数与利润预测数差异情况说明专项审核报告》(普华永道中天特审字(2013)第 720 号)。根据双方签订的补偿协议,由于从上实控股购入资产 2012 年所产生的归属于本公司的净利润未达到约定的金额,上海上实应在本公司 2012 年度财务报告披露之日起三十日内,以现金方式将差额部分人民币 2,225 万元一次性汇入本公司指定账户(详见公司公告临 2013-004 号),该笔款项的支付已于 2013 年 4 月 19 日完成。至此,该承诺已履行完毕。3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明□适用 √不适用3.5 报告期内现金分红政策的执行情况
    本公司根据《公司章程》规定的现金分红政策进行分红。2013 年 3 月 26 日,本公司第四届董事会第二十七次会议审议通过了《上海医药集团股份有限公司 2012 年度利润分配预案》,本公司 2012 年度利润分配预案为:拟以 2012 年 12 月 31 日股本总数 2,688,910,538 股为基数,向全体股东实施每 10股派发现金红利人民币 2.40 元(含税)。以上利润分配预案尚需提交本公司 2012 年度股东大会审议。
                                                                    上海医药集团股份有限公司
                                                                              法定代表人:周杰
                                                                            2013 年 4 月 27 日
    601607,02607                                         上海医药集团股份有限公司 2013 年第一季度报告§4附录4.1
                                      合并资产负债表
                                     2013 年 3 月 31 日编制单位: 上海医药集团股份有限公司
                                                  单位:元 币种:人民币 审计类型:未经审计
                    项目                              期末余额              年初余额流动资产:
    货币资金                                      12,914,801,874.27        13,525,398,266.52
    结算备付金
    拆出资金
    交易性金融资产                                       383,999.80             2,920,478.96
    应收票据                                       1,076,178,701.69         1,046,458,427.12
    应收账款                                      16,069,025,666.06        12,604,314,317.55
    预付款项                                         644,130,137.69           630,005,529.41
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                          24,458,861.09            15,333,869.26
    应收股利                                          72,545,812.30            21,027,811.90
    其他应收款                                       865,812,919.25           691,377,581.03
    买入返售金融资产
    存货                                           8,731,679,978.43         9,809,700,268.50
    一年内到期的非流动资产
    其他流动资产                                     130,348,810.68           455,393,423.90
       流动资产合计                                40,529,366,761.26        38,801,929,974.15非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                                     20,307,251.81          19,812,137.59
    持有至到期投资
    长期应收款                                        53,600,000.00
    长期股权投资                                   2,708,645,399.53         2,674,553,169.01
    投资性房地产                                     306,468,457.84           312,740,386.46
    固定资产                                       3,630,174,460.12         3,695,820,622.43
    在建工程                                         716,005,501.43           557,875,552.02
    工程物资                                          13,359,980.73             5,739,925.93
    固定资产清理
    生产性生物资产                                         686,578.89              686,578.89
    油气资产
    无形资产                                       1,381,077,730.98         1,406,711,756.80
    开发支出
    商誉                                           3,191,703,824.19         3,172,826,135.09
    长期待摊费用                                     117,841,435.33           123,233,213.48
    递延所得税资产                                   186,589,455.02           191,744,163.85
    其他非流动资产                                    82,509,417.40           105,364,369.43
       非流动资产合计                              12,408,969,493.27        12,267,108,010.98
           资产总计                                52,938,336,254.53        51,069,037,985.13流动负债:
    短期借款                                       4,788,489,817.81         4,900,043,194.98
    601607,02607                                       上海医药集团股份有限公司 2013 年第一季度报告
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                      2,554,074,599.92         2,430,635,446.39
    应付账款                                     13,126,347,902.56        12,144,280,750.53
    预收款项                                        305,159,067.14           405,427,248.55
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                    329,298,095.79           363,900,530.59
    应交税费                                        485,520,160.09           415,867,008.66
    应付利息                                         28,737,393.72            21,731,283.11
    应付股利                                         46,127,975.58            58,928,069.75
    其他应付款                                    1,533,890,502.93         1,356,514,893.79
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                              730,000.00                730,000.00
    其他流动负债
      流动负债合计                               23,198,375,515.54        22,098,058,426.35非流动负债:
    长期借款                                         53,378,356.91             40,772,765.91
    应付债券
    长期应付款
    专项应付款                                          540,000.00               540,000.00
    预计负债                                         68,276,921.15            68,276,921.15
    递延所得税负债                                  278,176,735.65           282,348,608.09
    其他非流动负债                                  910,722,404.27           878,165,382.93
      非流动负债合计                              1,311,094,417.98         1,270,103,678.08
        负债合计                                 24,509,469,933.52        23,368,162,104.43所有者权益(或股东权益):
    实收资本(或股本)                            2,688,910,538.00         2,688,910,538.00
    资本公积                                     14,443,339,890.63        14,445,888,302.33
    减:库存股
    专项储备
    盈余公积                                        802,126,846.36           802,126,846.36
    一般风险准备
    未分配利润                                    7,343,931,406.84         6,718,267,387.05
    外币报表折算差额                                -15,371,234.58           -15,893,737.54
    归属于母公司所有者权益合计                   25,262,937,447.25        24,639,299,336.20
    少数股东权益                                  3,165,928,873.76         3,061,576,544.50
          所有者权益合计                         28,428,866,321.01        27,700,875,880.70
        负债和所有者权益总计                     52,938,336,254.53        51,069,037,985.13
    公司法定代表人: 周杰 主管会计工作负责人:徐国雄    会计机构负责人:沈波
    601607,02607                                         上海医药集团股份有限公司 2013 年第一季度报告
                                     母公司资产负债表
                                     2013 年 3 月 31 日编制单位: 上海医药集团股份有限公司
                                                     单位:元 币种:人民币 审计类型:未经审计
                    项目                             期末余额              年初余额流动资产:
    货币资金                                      1,309,648,587.32          1,388,629,534.28
    交易性金融资产
    应收票据
    应收账款                                             12,086,873.08          12,086,873.08
    预付款项
    应收利息                                         28,536,378.00             14,767,120.38
    应收股利                                        175,604,133.13            122,365,372.40
    其他应收款                                    8,336,726,021.34          8,120,180,021.66
    存货
    一年内到期的非流动资产
    其他流动资产
       流动资产合计                                9,862,601,992.87          9,658,028,921.80非流动资产:
    可供出售金融资产                                      1,112,870.85           1,022,024.25
    持有至到期投资
    长期应收款
    长期股权投资                                 13,278,080,776.37         13,252,301,090.05
    投资性房地产                                     11,195,312.50             11,195,312.50
    固定资产                                        136,158,450.06            141,695,533.40
    在建工程                                          3,998,541.74              3,333,447.42
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                             30,569,883.38          31,343,899.68
    开发支出
    商誉
    长期待摊费用                                         16,020,418.70          17,195,530.37
    递延所得税资产
    其他非流动资产
       非流动资产合计                             13,477,136,253.60         13,458,086,837.67
          资产总计                                23,339,738,246.47         23,116,115,759.47流动负债:
    短期借款                                         400,000,000.00           400,000,000.00
    交易性金融负债
    应付票据
    应付账款                                              6,846,577.23          11,369,247.23
    预收款项                                              4,207,189.17           4,207,189.17
    应付职工薪酬                                          6,638,660.07          14,319,669.14
    应交税费                                             25,698,412.94          27,350,309.53
    应付利息                                                666,666.67             666,666.67
    应付股利
    其他应付款                                    2,120,320,607.09          1,915,896,562.02
    601607,02607                                           上海医药集团股份有限公司 2013 年第一季度报告
    一年内到期的非流动负债
    其他流动负债
      流动负债合计                              2,564,378,113.17               2,373,809,643.76非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                    244,580.80                     221,869.15
    其他非流动负债                                 38,557,969.51                  26,686,136.36
      非流动负债合计                               38,802,550.31                  26,908,005.51
        负债合计                                2,603,180,663.48               2,400,717,649.27所有者权益(或股东权益):
    实收资本(或股本)                          2,688,910,538.00               2,688,910,538.00
    资本公积                                   16,371,051,438.43              16,370,983,303.48
    减:库存股
    专项储备
    盈余公积                                      431,017,621.26                 431,017,621.26
    一般风险准备
    未分配利润                                  1,245,577,985.30               1,224,486,647.46
    所有者权益(或股东权益)合计                   20,736,557,582.99              20,715,398,110.20
        负债和所有者权益(或股东权益)总计     23,339,738,246.47              23,116,115,759.47公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波4.2
                                       合并利润表
                                     2013 年 1—3 月编制单位: 上海医药集团股份有限公司
                                                  单位:元 币种:人民币 审计类型:未经审计
                     项目                             本期金额              上期金额
    一、营业总收入                                   19,590,198,049.21     16,657,603,310.67
    其中:营业收入                               19,590,198,049.21     16,657,603,310.67
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                   18,850,976,956.70           15,994,529,868.36
    其中:营业成本                               16,974,840,994.14           14,328,824,836.80
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额
           保单红利支出
           分保费用
           营业税金及附加                             66,158,111.66               46,319,439.76
           销售费用                                1,104,349,834.48              986,111,884.32
           管理费用                                  662,548,468.76              570,448,582.31
           财务费用                                   32,243,253.75               65,245,006.85
    601607,02607                                           上海医药集团股份有限公司 2013 年第一季度报告
              资产减值损失                                 10,836,293.91           -2,419,881.68
        加:公允价值变动收益(损失以“-”号填
                                                             -29,675.00               -72,365.22列)
            投资收益(损失以“-”号填列)              146,723,795.40           148,120,829.90
              其中:对联营企业和合营企业的投资
                                                        149,633,828.36           129,529,638.78收益
        汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                      885,915,212.91           811,121,906.99
    加:营业外收入                                        9,729,250.68            25,980,005.00
    减:营业外支出                                        1,059,420.21             5,638,439.82
      其中:非流动资产处置损失                               66,299.57             1,005,900.00
    四、利润总额(亏损总额以“-”号填列)                  894,585,043.38           831,463,472.17
    减:所得税费用                                      157,754,803.57           150,935,584.19
    五、净利润(净亏损以“-”号填列)                      736,830,239.81           680,527,887.98
    归属于母公司所有者的净利润                          625,664,019.79           576,568,772.74
    少数股东损益                                        111,166,220.02           103,959,115.24六、每股收益:
    (一)基本每股收益                                         0.2327                    0.2144
    (二)稀释每股收益                                         0.2327                    0.2144
    七、其他综合收益                                           753,677.75               -141,196.87
    八、综合收益总额                                       737,583,917.56            680,386,691.11
    归属于母公司所有者的综合收益总额                   625,850,034.55            576,427,575.87
    归属于少数股东的综合收益总额                       111,733,883.01            103,959,115.24
    公司法定代表人: 周杰 主管会计工作负责人:徐国雄       会计机构负责人:沈波
                                         母公司利润表
                                         2013 年 1—3 月编制单位: 上海医药集团股份有限公司
                                                     单位:元 币种:人民币 审计类型:未经审计
                       项目                              本期金额              上期金额
    一、营业收入                                                178,065.10            189,724.00
      减:营业成本
          营业税金及附加                                                               10,719.40
          销售费用
          管理费用                                         31,983,406.42          25,568,241.47
          财务费用                                         -3,828,964.20         -65,104,195.25
          资产减值损失
      加:公允价值变动收益(损失以“-”号填列)
          投资收益(损失以“-”号填列)                   49,029,686.32           42,276,821.09
            其中:对联营企业和合营企业的投资
                                                           49,029,686.32           30,606,821.09收益
    二、营业利润(亏损以“-”号填列)                        21,053,309.20           81,991,779.47
      加:营业外收入                                           43,570.00            3,300,011.89
      减:营业外支出                                            5,541.36
        其中:非流动资产处置损失
    三、利润总额(亏损总额以“-”号填列)                    21,091,337.84           85,291,791.36
      减:所得税费用                                                               13,671,242.53
    四、净利润(净亏损以“-”号填列)                        21,091,337.84           71,620,548.83五、每股收益:
    601607,02607                                           上海医药集团股份有限公司 2013 年第一季度报告
    (一)基本每股收益
    (二)稀释每股收益
    六、其他综合收益                                           68,134.95                 -128,320.82
    七、综合收益总额                                       21,159,472.79               71,492,228.01
    公司法定代表人: 周杰 主管会计工作负责人:徐国雄     会计机构负责人:沈波4.3
                                     合并现金流量表
                                     2013 年 1—3 月编制单位: 上海医药集团股份有限公司
                                                   单位:元 币种:人民币 审计类型:未经审计
                      项目                             本期金额              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                  19,948,027,866.34          16,625,698,591.10
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                    15,931,721.93              15,862,983.67
    收到其他与经营活动有关的现金                     264,592,713.71             810,229,893.38
       经营活动现金流入小计                        20,228,552,301.98          17,451,791,468.15
    购买商品、接受劳务支付的现金                  17,911,958,804.33          14,835,163,832.10
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                   856,177,488.13             741,018,267.48
    支付的各项税费                                   746,912,935.97             494,489,013.03
    支付其他与经营活动有关的现金                     971,329,319.48           1,405,596,762.18
       经营活动现金流出小计                        20,486,378,547.91          17,476,267,874.79
          经营活动产生的现金流量净额                 -257,826,245.93             -24,476,406.64二、投资活动产生的现金流量:
    收回投资收到的现金                                  3,261,069.89
    取得投资收益收到的现金                              1,982,000.00               2,872,191.30
    处置固定资产、无形资产和其他长期资产收
                                                         1,115,369.20              18,821,026.06回的现金净额
    处置子公司及其他营业单位收到的现金净额             50,754,258.33              42,610,945.02
    收到其他与投资活动有关的现金                       71,820,765.19              25,425,997.92
       投资活动现金流入小计                            128,933,462.61              89,730,160.30
    购建固定资产、无形资产和其他长期资产支
                                                       254,629,746.75            116,668,810.26付的现金
    投资支付的现金                                      7,825,272.00
    601607,02607                                       上海医药集团股份有限公司 2013 年第一季度报告
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额         22,533,928.56              74,874,698.45
    支付其他与投资活动有关的现金                   76,041,579.34              13,809,464.52
      投资活动现金流出小计                        361,030,526.65             205,352,973.23
        投资活动产生的现金流量净额               -232,097,064.04            -115,622,812.93三、筹资活动产生的现金流量:
    吸收投资收到的现金                             13,720,000.00               2,000,000.00
    其中:子公司吸收少数股东投资收到的现金         13,720,000.00               2,000,000.00
    取得借款收到的现金                          2,942,926,720.32           1,791,524,795.49
    发行债券收到的现金
    收到其他与筹资活动有关的现金
      筹资活动现金流入小计                      2,956,646,720.32           1,793,524,795.49
    偿还债务支付的现金                          2,939,593,862.20           1,929,985,629.59
    分配股利、利润或偿付利息支付的现金            128,720,682.79             163,493,580.95
    其中:子公司支付给少数股东的股利、利润         21,937,870.27              19,990,452.47
    支付其他与筹资活动有关的现金                    3,820,319.56              31,297,565.86
      筹资活动现金流出小计                      3,072,134,864.55           2,124,776,776.40
        筹资活动产生的现金流量净额               -115,488,144.23            -331,251,980.91
    四、汇率变动对现金及现金等价物的影响               -1,446,115.25               9,040,354.22
    五、现金及现金等价物净增加额                     -606,857,569.45            -462,310,846.26
    加:期初现金及现金等价物余额               13,300,900,801.39          14,554,707,997.90
    六、期末现金及现金等价物余额                   12,694,043,231.94          14,092,397,151.64公司法定代表人: 周杰 主管会计工作负责人:徐国雄 会计机构负责人:沈波
                                     母公司现金流量表
                                     2013 年 1—3 月编制单位: 上海医药集团股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                     项目                           本期金额              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        178,065.10               189,724.00
    收到的税费返还
    收到其他与经营活动有关的现金                   201,516,409.86           236,905,239.99
       经营活动现金流入小计                         201,694,474.96           237,094,963.99
    购买商品、接受劳务支付的现金
    支付给职工以及为职工支付的现金                  16,386,185.99            14,327,474.04
    支付的各项税费                                   1,651,896.59                10,719.40
    支付其他与经营活动有关的现金                   148,048,902.46            73,116,385.91
       经营活动现金流出小计                         166,086,985.04            87,454,579.35
         经营活动产生的现金流量净额                  35,607,489.92           149,640,384.64二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金
    处置固定资产、无形资产和其他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额                                    41,170,000.00
    收到其他与投资活动有关的现金
       投资活动现金流入小计                                                    41,170,000.00
    购建固定资产、无形资产和其他长期资产支             6,716,212.41           24,827,161.64
    601607,02607                                      上海医药集团股份有限公司 2013 年第一季度报告付的现金
    投资支付的现金                                  30,000,000.00
    取得子公司及其他营业单位支付的现金净额                                    6,720,762.31
    支付其他与投资活动有关的现金                    71,858,000.00           503,880,000.00
      投资活动现金流出小计                         108,574,212.41           535,427,923.95
         投资活动产生的现金流量净额               -108,574,212.41          -494,257,923.95三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金
    发行债券收到的现金
    收到其他与筹资活动有关的现金
      筹资活动现金流入小计
    偿还债务支付的现金                                                      100,000,000.00
    分配股利、利润或偿付利息支付的现金               6,000,000.00            13,673,498.89
    支付其他与筹资活动有关的现金                                             16,167,600.00
      筹资活动现金流出小计                            6,000,000.00          129,841,098.89
         筹资活动产生的现金流量净额                  -6,000,000.00         -129,841,098.89
    四、汇率变动对现金及现金等价物的影响                    -14,224.47           10,377,368.92
    五、现金及现金等价物净增加额                       -78,980,946.96          -464,081,269.28
    加:期初现金及现金等价物余额                 1,388,629,534.28         8,608,621,502.40
    六、期末现金及现金等价物余额                     1,309,648,587.32         8,144,540,233.12
    公司法定代表人: 周杰 主管会计工作负责人:徐国雄   会计机构负责人:沈波
数据加载中...
prevnext
手机查看股票